Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06581393 · ClinicalTrials.gov registry record · NA

First Evaluation of the Moda-Flx Hemodialysis System™ in Real World Clinical Settings

A NA study of End Stage Renal Disease and End-Stage Kidney Disease, sponsored by Diality.

Completed
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT06581393 is a NA study of End Stage Renal Disease and End-Stage Kidney Disease that has completed, run by Diality. The registered enrollment target is 12 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06581393, a NA study of End Stage Renal Disease and End-Stage Kidney Disease, has completed, sponsored by Diality.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This is a non-significant risk study utilizing a device cleared for use by the FDA under its 510(k) clearance. Consented patients will complete their usual dialysis treatment under professional care in an ICHD (In-Center Hemodialysis) setting.

Interventions

  • DEVICE Moda-flx Hemodialysis System

Study Locations (1)

California

  • North America Research Institute - Ontario

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2024-12-09
Est. Completion 2025-04-28
Phase NA

Sponsor

Diality

2 total trials

What the Registry Record Tells You About NCT06581393

The ClinicalTrials.gov registry entry for NCT06581393 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower). The listed sponsor is Diality, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Moda-flx Hemodialysis System is the first listed.

NCT06581393 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06581393 about?

NCT06581393 is a clinical study titled "First Evaluation of the Moda-Flx Hemodialysis System™ in Real World Clinical Settings". This is a non-significant risk study utilizing a device cleared for use by the FDA under its 510(k) clearance. Consented patients will complete their usual dialysis treatment under professional care in an ICHD (In-Center Hemodialysis) setting.

What is the current status of trial NCT06581393?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2024-12-09. Estimated completion is 2025-04-28.

What conditions does trial NCT06581393 study?

This clinical trial studies the following conditions: End Stage Renal Disease, End-Stage Kidney Disease, End Stage Renal Disease on Dialysis.

What interventions are being tested in trial NCT06581393?

The interventions under investigation include: Moda-flx Hemodialysis System (DEVICE).

Who is sponsoring clinical trial NCT06581393?

This trial is sponsored by Diality, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06581393 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for End Stage Renal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.